Intravascular Ultrasound–Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery

Abstract

Postprocedure MSA can predict ISR in SFA lesions, which suggests that adequate stent enlargement during angioplasty might be required for superior patency.

Histological Evaluation of a Self-Expanding Stent-Graft 23 Months After Implantation in the Superficial Femoral Artery

“…Generally, smaller stent area and longer lesion length are associated with restenosis after bare metal or drug-eluting stent implantation because neointimal proliferation occurs in any part of the stented segment and leads to lumen stenosis. 3,4 Our finding that no neointimal proliferation was found other than at the edges corresponds to a lack of association of lesion length and device diameter with restenosis.…”

Preprocedural Mean Platelet Volume Level Is a Predictor of In-Stent Restenosis of the Superficial Femoral Artery Stents in Follow-Up

“…Therefore, it is very important to know the clinical features that may cause in-stent restenosis. It has been demonstrated that many parameters including diabetes mellitus, smoking, dyslipidemia, long complex lesions, and age are predictors of the in-stent restenosis after SFA interventions in the follow-up [ 16 , 17 ]. The rates of in-stent restenosis can be decreased by taking several precautions to these clinical features.…”

Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals

“…If a significant adjusted mortality difference was found between races, a prespecified mediation analysis was planned to investigate the potential role of variations in procedural and postprocedural care in driving this difference. Procedural and postprocedural factors considered in the analyses included the following: (1) the use of advanced intracoronary imaging or physiologic testing (fractional flow reserve [FFR], 22 intravascular ultrasound [IVUS], 23 or optical coherence tomography [OCT]); (2) bare-metal stent (BMS) vs drug-eluting stent (DES) use; (3) incomplete revascularization; (4) radial access use; and (5) postprocedural medication prescriptions (high-intensity statins, β-blockers, angiotensin-converting enzyme inhibitor [ACEi] or aldosterone receptor blocker [ARB] therapy, and clopidogrel bisulfate, ticagrelor, or prasugrel). Performance of FFR, IVUS, or OCT included the use of this technology during the diagnostic catheterization, PCI, or both.…”